Healios K.K. (OTCMKTS:HLOSF – Get Free Report) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 148,399 shares, a decrease of 57.3% from the December 31st total of 347,749 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Healios K.K. Stock Performance
Shares of Healios K.K. stock opened at $2.10 on Friday. Healios K.K. has a fifty-two week low of $1.90 and a fifty-two week high of $4.45. The stock has a 50 day moving average of $2.33 and a 200 day moving average of $3.29.
Healios K.K. Company Profile
Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.
Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.
Recommended Stories
- Five stocks we like better than Healios K.K.
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
